The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety and Tolerability of SPD489 in Adults Aged 18-55
|Effective start/end date||12/11/12 → 5/31/14|
- Shire Development Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.